TD Asset Management Inc. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 16.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 78,187 shares of the life sciences company’s stock after purchasing an additional 10,799 shares during the period. TD Asset Management Inc.’s holdings in Illumina were worth $23,451,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Financial Enhancement Group LLC bought a new stake in Illumina during the 3rd quarter worth about $400,000. Nan Shan Life Insurance Co. Ltd. bought a new stake in Illumina during the 3rd quarter worth about $52,099,000. Handelsbanken Fonder AB bought a new stake in Illumina during the 3rd quarter worth about $8,442,000. Hall Laurie J Trustee raised its holdings in Illumina by 61.8% during the 3rd quarter. Hall Laurie J Trustee now owns 890 shares of the life sciences company’s stock worth $327,000 after purchasing an additional 340 shares during the last quarter. Finally, Pacer Advisors Inc. raised its holdings in Illumina by 18.2% during the 3rd quarter. Pacer Advisors Inc. now owns 13,597 shares of the life sciences company’s stock worth $4,991,000 after purchasing an additional 2,092 shares during the last quarter. Institutional investors own 88.94% of the company’s stock.
Shares of ILMN stock opened at $284.10 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.49 and a quick ratio of 2.24. The stock has a market capitalization of $40.65 billion, a PE ratio of 49.67, a P/E/G ratio of 1.98 and a beta of 1.20. Illumina, Inc. has a one year low of $210.08 and a one year high of $372.61.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The company had revenue of $867.00 million during the quarter, compared to the consensus estimate of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. The business’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $1.44 earnings per share. As a group, sell-side analysts expect that Illumina, Inc. will post 6.51 earnings per share for the current fiscal year.
In related news, SVP Charles Dadswell sold 566 shares of the business’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $343.57, for a total value of $194,460.62. Following the completion of the transaction, the senior vice president now directly owns 5,606 shares in the company, valued at approximately $1,926,053.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The shares were sold at an average price of $312.50, for a total value of $1,031,250.00. Following the completion of the transaction, the director now owns 376,710 shares of the company’s stock, valued at $117,721,875. The disclosure for this sale can be found here. Insiders sold a total of 49,247 shares of company stock valued at $15,204,166 over the last quarter. 0.54% of the stock is owned by insiders.
ILMN has been the subject of several recent research reports. Zacks Investment Research cut Illumina from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. Morgan Stanley dropped their price objective on Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a report on Monday, January 7th. Deutsche Bank cut Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective for the company. in a report on Friday, January 25th. Bank of America reissued a “buy” rating and set a $355.00 price objective on shares of Illumina in a report on Wednesday, January 30th. Finally, Leerink Swann raised Illumina to an “outperform” rating and dropped their price objective for the stock from $380.00 to $365.00 in a report on Wednesday, January 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Illumina has an average rating of “Buy” and an average price target of $346.40.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Further Reading: Quiet Period
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.